Development and Testing of Novel Interventions to Improve HIV Prevention, Treatment, and Program Implementation for People Who Use Substances (R34 Clinical Trial Required)
Developing and testing new interventions to enhance HIV prevention, treatment, and programs for individuals who use substances through formative research and pilot-testing.
Funder: National Institutes of Health
Due Dates: November 16, 2026 (Resubmission schedule) | February 16, 2027 (New application schedule) | March 16, 2027 (Resubmission schedule)
Funding Amounts: Up to $450,000 in direct costs over 3 years, with no more than $225,000 in any year
Summary: Supports development and pilot testing of HIV prevention, treatment, and implementation interventions for people who use substances.
Key Information: Clinical trials and meaningful end-user engagement are required; alcohol-only studies are not responsive.
Description
The National Institute on Drug Abuse (NIDA), part of NIH, supports formative research, intervention development, and pilot or feasibility studies through this R34 planning grant. The program focuses on the feasibility, tolerability, acceptability, and safety of new or adapted interventions addressing HIV prevention, treatment, and services for people who use drugs. Interventions may use behavioral, social, structural, or combined biomedical and behavioral approaches.
Supported work includes preventing HIV acquisition and transmission, improving HIV care and viral suppression, integrating substance use and HIV treatment, and overcoming barriers to effective services. Domestic and overseas studies are considered, particularly those addressing populations disproportionately affected by HIV. Projects should inform future large-scale efficacy, effectiveness, or implementation trials and consider intervention sustainability and scalability from the pilot stage.
